KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Change in Accured Expenses (2017 - 2025)

Guardant Health (GH) has disclosed Change in Accured Expenses for 9 consecutive years, with $53.7 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 216.28% to $53.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $52.7 million through Dec 2025, up 1970.53% year-over-year, with the annual reading at $52.7 million for FY2025, 1970.53% up from the prior year.
  • Change in Accured Expenses hit $53.7 million in Q4 2025 for Guardant Health, up from $3.3 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $53.7 million in Q4 2025 to a low of -$28.3 million in Q2 2024.
  • Historically, Change in Accured Expenses has averaged $7.5 million across 5 years, with a median of $4.3 million in 2021.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 1240.85% in 2021 and later plummeted 1176.35% in 2024.
  • Year by year, Change in Accured Expenses stood at $24.2 million in 2021, then tumbled by 43.83% to $13.6 million in 2022, then crashed by 257.08% to -$21.4 million in 2023, then soared by 179.46% to $17.0 million in 2024, then surged by 216.28% to $53.7 million in 2025.
  • Business Quant data shows Change in Accured Expenses for GH at $53.7 million in Q4 2025, $3.3 million in Q3 2025, and -$2.7 million in Q2 2025.